

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Extrawell Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Wu Xiangyun (“**Mr. Wu**”) has been appointed as an executive director of the Company with effect from 12 October 2026.

The biographical details of Mr. Wu are as follows:

Mr. Wu, aged 32, specializes in the full lifecycle management of electronic components, server supply chains, and data center projects, with extensive experience in cross-border trade, supplier integration, and compliance risk control. As at the date of this announcement, Mr. Wu is a director of a wholly owned subsidiary of the Group engaged in trading business. He has been the general manager of this subsidiary since August 2026 and was appointed as a director of this subsidiary in September 2026. Prior to joining the Group, Mr. Wu served as an auditor at an accountant firm and held the positions of project manager and general manager at software and supply chain management companies, in mainland China. Mr. Wu obtained a Bachelor’s Degree in Management Studies from Zhengzhou University in 2017 and a Master’s Degree in International Management (Business Management) from Clermont School of Business, France in 2026.

Mr. Wu has entered into a letter of appointment with the Company as an executive director of the Company for a term commencing from 12 October 2026 until terminated by either party by giving not less than two months’ prior written notice to the other party. Mr. Wu will hold office until the first annual general meeting of the Company after his appointment but will then be eligible for re-election at that annual general meeting and thereafter he shall be subject to retirement by rotation and re-election at the annual general meetings in accordance with the bye-laws of the Company. Mr. Wu is currently entitled to a remuneration which is comprised of a monthly salary of HK\$40,000, a year-end bonus equivalent to his one month’s salary (pro-rated to his length of service if less than a whole year) and a director’s fee of HK\$70,000 per annum, covering his services as an executive director of the Company and other role and position with any subsidiary of the Group. Mr. Wu is also entitled to share options to be granted under the share option scheme of the Company subject to the approval of the Board and/

or the remuneration committee of the Company. Mr. Wu's remuneration package was determined by the Board with reference to the recommendation of the remuneration committee of the Company, based on his background, qualifications, experience, his roles and responsibilities within the Company, and the current market conditions.

Mr. Wu has obtained the legal advice pursuant to Rule 3.09D of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") on 6 October 2026.

Save as disclosed above, as at the date of this announcement, Mr. Wu has confirmed that he (i) does not hold any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years immediately preceding the date of this announcement; (ii) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholders (having the meaning ascribed to them under the Listing Rules) of the Company; (iv) does not hold any other positions with any member of the Group; and (v) does not have other major appointments or professional qualifications.

Save as disclosed above, the Board is not aware of other information relating to the appointment of Mr. Wu required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company concerning the appointment of Mr. Wu as an executive director of the Company.

The Board welcomes Mr. Wu to the Board.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 12 October 2026

As at the date of this announcement, the executive directors are Dr. Xie Yi, Dr. Guo Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen and Mr. Wu Xiangyun, and the independent non-executive directors are Ms. Jin Song, Dr. Zeng Li and Ms. Yang Xiaorong.

* *For identification purpose only*